Zydus, China Medical System enter licensing agreement for desidustat

Under the license agreement, CMS will pay Zydus an initial upfront payment, regulatory milestones, sales milestones and royalties on net sales of the product. The commercial terms of the license agreement are confidential. CMS will be responsible for the development, registration and commercialization of Desidustat in Greater China.

Ahmedabad: Zydus, a discovery-based global pharmaceutical company today announced that it has entered into a licensing agreement with China Medical System Holdings Limited (CMS) for the development and commercialization of Desidustat, a novel oral HIF-PH inhibitor for the treatment of anaemia in patients with Chronic Kidney Disease (CKD) not-on-dialysis and for the treatment of Anemia CKD patients on dialysis in Greater China (Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan).

It has been reported that more than 120 million people are estimated to be living with CKD in China1 (Source: Zhang L, Wang F, Wang L et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 2012; 379: 815–822). CKD is a serious medical condition which is an unmet healthcare need involving gradual loss of functioning of kidneys eventually leading to kidney failure. If kidneys are healthy they will naturally secrete beneficial levels of a hormone called erythropoietin (EPO), which encourages red blood cell production that carries oxygen to the muscles and brain. If the kidneys are impaired they will produce reduced levels or tire of EPO production completely, leading to fatigue and anaemia.

Anaemia is one of the frequent complications of CKD. A survey in China showed that the prevalence of anaemia in patients at CKD stage 1 to 5 was 22.0%, 37.0%, 45.4%, 85.1%, and 98.2%, respectively2. The target-achieving rate was only 8.2% for anaemia patients in nondialysis CKD and 35.2% for dialysis CKD, showing unmet healthcare need3.

Speaking on the development, Pankaj R. Patel, Chairman, Zydus Group said, "The licensing agreement with CMS will facilitate the development and commercialization of Desidustat in Greater China, and make this innovative candidate available to millions of CKD patients living with anaemia."

Under the license agreement, CMS will pay Zydus an initial upfront payment, regulatory milestones, sales milestones and royalties on net sales of the product. The commercial terms of the license agreement are confidential. CMS will be responsible for the development, registration and commercialization of Desidustat in Greater China.

Read also: Zydus Cadila unveils affordable anti-diabetic drug Vildagliptin under brands Vinglyn, Vinglyn M

Zydus had initiated two Phase III trials of Desidustat. The DREAM-ND (ClinicalTrials.gov Identifier: NCT04012957) Phase III trial is being conducted in CKD patients not-on-dialysis. The DREAM-D Phase III trial (ClinicalTrials.gov Identifier: NCT04215120) is being conducted in CKD patients on Dialysis. Desidustat had previously met its primary endpoints in Phase II clinical studies and showed a good safety profile. The Phase I trials were earlier completed in Australia. 

Read also: Zydus Cadila to divest two major units- Vivo, Gynova for Rs 1200 crore: Report